Data shows efficacy and safety of Desvocy for PrEP

Data shows efficacy and safety of Desvocy for PrEP
Cedit: Marc Bruxelle

Gilead Sciences has reported 96-week results from the DISCOVER trial evaluating the safety and efficacy of once-daily Descovy for HIV pre-exposure prophylaxis (PrEP) compared with Truvada for PrEP, in men and transgender women who have sex with men and are at risk for sexually acquired HIV infection.

Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg) demonstrated non-inferior efficacy to Truvada (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg) through 96 weeks and statistically significant differences over Truvada for certain key measurements of bone and renal safety assessed in the study, which were pre-specified secondary endpoints.

“The 96-week data from the DISCOVER trial further support the comparable efficacy of Descovy and Truvada for PrEP and offer new insights into the improved renal and bone safety profile of Descovy as measured by key bone and renal markers,” said Diana Brainard, Senior Vice President of HIV and Emerging Viruses at Gilead Sciences.

“As more at-risk people use PrEP for longer periods of time, the data affirm the value of Descovy for PrEP as a new HIV prevention option.”